Complex regional pain syndrome (CRPS) market would be valued approximately USD 103.7 million in 2023. The market is anticipated to grow at a compound annual growth rate (CAGR) of 2.2% between 2023 and 2033. The market is expected to grow positively throughout the forecast years, reaching USD 129.2 million by 2033, according to the analytical report by FMI.
The market is developing primarily due to the rise in the number of people with failing back syndrome, chronic pain, and complex regional pain syndrome (CRPS). A chronic pain condition that can affect the entire body or just the hands, feet, arms, and legs is called complex regional pain syndrome, or CRPS.
Get Your Insightful – Report Sample
The increase in the number of persons suffering from complex regional pain syndrome (CRPS), chronic pain, and failing back syndrome is one of the main drivers of market expansion. Complex regional pain syndrome (CRPS) is a chronic pain disorder that can affect one’s entire body or only the hands, feet, arms, and legs.
Both of the two forms of CRPS have the same symptoms and available treatments. Complex Regional Pain Syndrome (CRPS) Type I, sometimes referred to as reflex sympathetic dystrophy, appears following an injury without any nerve damage. Type II CRPS may occur as a result of specific nerve injury or trauma.
Key Takeaways:
- The global complex regional pain syndrome (CRPS) market is estimated to reach USD129.2 million by 2033, reflecting a rise from USD103.7 million in 2023.
- This growth is projected at a steady compound annual growth rate (CAGR) of 2.2% throughout the forecast period.
- The rising prevalence of CRPS and chronic pain conditions are key drivers for market expansion
Market Competition:
Mallinckrodt Pharmaceuticals, GlaxoSmithKline plc. Mylan N.V., Teva Pharmaceutical Industries Ltd., AbbVie, ACTAVIS, Zydus Pharmaceuticals, Inc., Sandoz, and Janssen Global Services, LL. are among the leading companies operating in the market.
Recent Developments in the Complex Regional Pain Syndrome (CRPS) Market
- In August 2022, GSK plc announced the New Drug Application (NDA) for momelotinib, a potential new medicine with a proposed differentiated mechanism of action. It may address the significant unmet medical needs of myelofibrosis patients with anemia, which had been accepted by the US Food and Drug Administration (FDA).
- In June 2022, Mallinckrodt plc, a global biopharmaceutical company announced the resubmission of the Company’s New Drug Application (NDA) to the USA Food and Drug Administration (FDA) for the investigational agent terlipressin. It helps to treat adults with hepatorenal syndrome (HRS), an acute and life-threatening condition with no FDA-approved treatment.
Customization Available – Here
Key Companies Profiled:
- Mallinckrodt Pharmaceuticals
- GlaxoSmithKline plc.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- AbbVie
- ACTAVIS
- Zydus Pharmaceuticals Inc.
- Sandoz
- Janssen Global Services LLC.
- Medline Plus
Key Segments Profiled in the Complex Regional Pain Syndrome (CRPS) Industry Survey:
By Therapy Type:
- Physical Therapy
- Therapy via Drugs
- Analgesics
- Antidepressants
- Corticosteroids
- Others
- Surgical Sympathectomy
- Intrathecal Drug Pumps
- Spinal Cord Stimulation
By Route of Administration:
- Oral Therapy
- Intravenous Therapy
By Distribution Channel:
- Hospital Pharmacy
- Drug Stores
- Retail Pharmacy
- E-Commerce
By Region:
- North America
- Latin America
- Europe Complex
- Asia Pacific
- The Middle East and Africa
Get Full Market Analysis Now – Purchase The Report
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
